QbD Group helped a biotech company complete 5 site qualification visits in just 3 weeks enabling a timely and compliant clinical trial submission.
QbD Group helped a biotech company complete 5 site qualification visits in just 3 weeks enabling a timely and compliant clinical trial submission. Biotech company Clinical Medical Devices QbD Group supported a dynamic life sciences company driving innovation in chronic disease management in preparing for a timely submission to the Competent Authority (CA) for a new clinical study. Founded in 2021, the client focuses on developing technologies that improve the lives of patients with chronic degenerative conditions, particularly in the areas of musculoskeletal, connective tissue, and neurological disorders. With tight regulatory timelines and five preselected sites to qualify, QbD ensured that all Site Qualification Visits (SQVs) were completed, documented, and fully compliant within just three weeks—helping the client stay on track with their clinical development goals and mission to improve and prolong patients’ quality of life worldwide.
To ensure an on-time submission to the Competent Authority (CA), the client needed to complete Site Qualification Visits (SQVs) for five preselected clinical trial sites within a three-week timeframe. This required fast coordination, complete documentation, and real-time follow-up from the Clinical Research Associate (CRA)—without compromising regulatory compliance or operational quality.
The CRA contacted each of the five preselected sites to share preliminary study details and gauge interest.
Upon signature of a Confidential Disclosure Agreement (CDA), each site received the study protocol synopsis.
CRA collected the availability of the Principal Investigators (PIs) and study coordinators to schedule SQVs within the three-week window.
Thanks to transparent communication about the tight timeline, all sites committed to rapid scheduling.
Essential documents such as GCP certificates, CVs, and signed site suitability forms were requested in advance.
The CRA followed up persistently via email and phone to collect the required materials before the visits.
The site's ability to meet inclusion criteria and recruitment targets
Local processes for informed consent and source data collection
Access to EMRs, study coordinator support, and auxiliary departments (Pharmacy, Radiology)
A comprehensive visit report was prepared for each site, outlining all observations and assessments.
All documents and findings were submitted to the sponsor for review.
Upon sponsor decision, CRA communicated site selection status via official letters.
Through proactive planning, close collaboration, and hands-on coordination, QbD successfully completed and documented all five SQVs within the required three-week window. This allowed the client to submit its clinical study to the CA on time—meeting all compliance criteria and keeping the study launch on track.
Want to learn how to identify and manage risks during your clinical trial? Discover our expert strategies for minimizing uncertainty and ensuring trial success.
Read our practical guide on Clinical Trial Site Selection and Qualification
继续阅读
成功案例Fast-track your IVDR market access with our expertise. We help clients navigate regulatory hurdles to launch innovative diagnostic solutions efficiently and effectively.
阅读更多
成功案例Accelerate your market entry with our integrated IVDR and WHO strategy, ensuring compliance while minimizing costs and sample size for diagnostic tests.
阅读更多
成功案例Learn how we supported a global IVD manufacturer in achieving IVDR compliance for their multiplex STI PCR test, ensuring timely CE-marking and future regulatory confidence.
阅读更多